Substituted pyrimidinyl oxime kinase inhibitors

US8153791B2 · kind B2 · utility

Assignee

• Janssen Pharmaceutica NA · BE

Inventors

• Guozhang Xu · King of Prussia, US
• Lily Lee · New York, US
• Terry Vincent Hughes · Blue Bell, US
• Steven K. Wetter · Flemington, US
• Peter J. Connolly · New Providence, US
• Marta C. Abad · Downingtown, US
• Stuart Emanuel · Doylestown, US
• Prabha Saba Karnachi · Fryeburg, US
• Steven A. Middleton · Flemington, US
• Kathleen Battista · Williamstown, US
• Gilles Bignan · Bound Brook, US

Key dates

• Filing date: Dec 12, 2006
• Grant date: Apr 10, 2012
• Expiry date: Apr 11, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to substituted pyrimidine compounds of formula (I):and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.